Trial Profile
A 4-part Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of M254 in Healthy Volunteers and in Patients With Immune Thrombocytopenic Purpura
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs M-254 (Primary) ; Immune globulin
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Momenta Pharmaceuticals
- 19 Nov 2021 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 02 Aug 2021 Status changed from recruiting to discontinued.
- 31 Jul 2021 This trial has been completed in Netherlands (End Date: 08 Jun 2021), according to European Clinical Trials Database record.